Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parion, Santen Pharma to develop P-321 for dry eye disease
On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease.
On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease.
DiaPep277 is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds
Endonovo’s "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner
Partners will benefit from real-time multi-factorial analytics to design target-indication product concepts for rare diseases based on severity, epidemiology, gene ontology, pathways, proteinopathy, standard of care, emerging innovation,
The newly-issued patents are: US 8,729,293, US 8,735,378 and US 8,735,379. The method of use claims in these patents cover multiple inflammatory disease indications, including Duchenne muscular dystrophy
This entity was created to complement our other service offerings by providing guidance and support for all phases of the product life cycle, from product concept and early
The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases. Under the terms of the agreement, X-Chem is applying
Up to 500,000 doses of the vaccine will be manufactured, and the first doses will be available in September. ASD Specialty Healthcare and its Besse Medical and Oncology
Livatag was already patented until 2019 with a first patent family covering the pharmaceutical product’s composition. The second one covers the specific administration scheme of Livatag, strengthening and
These three antigens are in addition to the Company’s agglutinin-like sequence 3 (Als3) antigen used in NDV-3, NovaDigm’s lead vaccine being evaluated in an on-going Phase 1b/2a study.